Augmented induction of CD8+ cytotoxic T-cell response and antitumor effect by DCs pulsed with virus-like particles packaging with CpG

Cancer Letters

Volumn 256, Issue 1, 2007, Pages 90-100

  Song, Shuxia ^a   Wang, Yue ^a   Zhang, Yan ^b   Wang, Fang ^a   He, Ying ^a   Ren, Ding ^a   Guo, Yingjun ^a   Sun, Shuhan ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Antitumoral experiment; CpG; CTL; DCs; HBc VLP

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; HEPATITIS B CORE ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG EFFECT; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR IMMUNITY; VACCINATION; VIRUS LIKE AGENT;

ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DENDRITIC CELLS; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION; IMMUNOTHERAPY; INTERFERON-GAMMA; MICE; MICE, TRANSGENIC; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; VIRION;

ANIMALIA; MUS;

EID: 34548202142     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.06.004     Document Type: Article

References (34)

1. Sheng K.C., Pietersz G.A., Wright M.D., and Apostolopoulos V. Dendritic cells: activation and maturation-applications for cancer immunotherapy. Curr. Med. Chem. 12 (2005) 1783-1800
2. Huang A.Y.C., Golumbeck P., Ahmadzadeh M., Jaffee E., Pardoll D., and Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264 (1994) 961-965
3. Albert M.L., Sauter B., and Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392 (1998) 86-89
4. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18 (2000) 767-811
5. de Saint-Vis B., Fugier-Vivier I., Massacrier C., Gaillard C., Vanbervliet B., Ait-Yahia S., et al. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J. Immunol. 160 (1998) 1666-1676
6. Silvija J.J., Rolf D.P., Stein S.L., Finn W., and Gustav G. Evaluation of dedritic cells loaded with apoptotic cancer cells or expressing tumor mRNA as potential cancer vaccinea against leukemia. BMC Cancer 5 (2005) 20-29
7. Rohn T.A., Schadendorf D., Sun Y., Nguyen X.D., Roeder D., Langen H., Vogt A.B., and Kropshofer H. Melanoma cell necrosis facilitates transfer of specific sets of antigens onto MHC class II molecules of dendritic cells. Eur. J. Immunol. 35 (2005) 2826-2839
8. Moron V.G., Rueda P., Sedlik C., and Leclerc C. In vivo, dedritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway. J. Immunol. 171 (2003) 2242-2250
9. He Y.K., Zhang J.Y., Mi Z.B., Robbins Jr. P., and Falo L.D. Immunization with lentiviral vector-transduced dedritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J. Immunol. 174 (2005) 3808-3817
10. Zehn D., Cohen C.J., Reiter Y., and Walden P. Extended presentation of specific MHC-peptide complexes by mature dendritic cells compared to other types of antigen-presenting cells. Eur. J. Immunol. 34 (2004) 1551-1560
11. Nardin E.H., Oliveira G.A., Calvo-Calle J.M., Wetzel K., Maier C., Birkett A.J., Sarpotdar P., et al. Phase I testing of a Malaria vaccine composed of Hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect Immun. 72 (2004) 6519-6527
12. Lenz P., Thompson C.D., Day P.M., Bacot S.M., Lowy D.R., and Schiller J.T. Interaction of Papillomavirus-like particles with human myeloid antigen-presenting cells. Clin. Immunol. 106 (2003) 231-237
13. Petra L., Patricia M.D., Yuk-Ying S.P., Stephan A.F., Peter N.J., Douglas R.L., and John T.S. Papillomavirus-like particles induce acute activation of dendritic cells. J. Immunol. 166 (2001) 5346-5355
14. Tazio S., Franziska L., Iris E., Thomas B., Andrea J., Tilman D., Thomas M.K., et al. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J. Immunol. 168 (2002) 2880-2886
15. Takeda K., Kaisho T., and Akira S. Toll-like receptors. Annu. Rev. Immunol. 21 (2003) 335-376
16. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20 (2002) 709-760
17. Chagnon F., Tanguay S., Ozdal O.L., Guan M., Ozen Z.Z., Ripeau J.S., Mario C., et al. Potentiation of a dentritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides. Clin. Cancer Res. 11 (2005) 1302-1311
18. Storni T., Ruedl C., Schwarz K., Schwendener R.A., Renner W.A., and Bachmann M.F. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J. Immunol. 172 (2004) 1777-1785
19. Schwarz K., Meijerink E., Speiser D.E., Tissot A.C., Cielens I., Renhof R., and Dishlers A. Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles. Eur. J. Immonol. 35 (2005) 816-821
20. Lutz M.B., Kukutsch N., Ogilvie A.L.J., RoBner S., Koch F., Romani N., and Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223 (1999) 77-92
21. Ren D., Wang F., He X., Jiang L., Li D., Ying H., and Sun S. Construction of bioactive chimeric MHC class I tetramer by expression and purification of human-murine chimeric MHC heavy chain and β(2)m as a fusion protein in Escherichia coli. Protein Expr. Purif. 50 (2006) 171-178
22. Barchet W., Oehen S., Klenerman P., Wodarz D., Bocharov G., Lloyd A.L., Nowak M.A., et al. Direct quantitation of rapid elimination of viral antigen-positive lymphocytes by antiviral CD8(+) T cells in vivo. Eur. J. Immunol. 30 (2000) 1356-1363
23. Song S., Wang F., He X., He Y., Li D., and Sun S. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line co-expressing HLA-A2/H-2kb and HCC-derived CTL multiepitope in HLA transgenic mice. Vaccine 25 (2007) 4853-4860
24. Thurner B., Haendle I., Roder C., Dieckmann D., Keikavoussi P., Jonuleit H., Bender A., et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 90 (1999) 1669-1678
25. Yu Z., and Restifo N.P. Cancer vaccines: progress reveals new complexities. J. Clin. Invest. 110 (2002) 289-294
26. 205 molecules. J. Exp. Med. 195 (2002) 1233-1245
27. Rongcun Y., Murillo F.M., Cui H., Blosser R., Uematsu S., Takeda K., Akira S., Viscidi R.P., and Roden R.B.S. Papillomavirus-Like Particles Stimulate Murine Bone Marrow-Derived Dendritic Cells To Produce Alpha Interferon and Th1 Immune Responses via MyD88. J. Virol. 78 (2004) 11152-11160
28. + T-helper and a T-killer cell. Nature 393 (1998) 474-478
29. Eduardo D., Kennedy R., and Celis E. Generation of Antitumor Immunity by Cytotoxic T Lymphocyte Epitope Peptide Vaccination, CpG-oligodeoxynucleotide Adjuvant, and CTLA-4 Blockade. Cancer Res. 63 (2003) 3281-3288
30. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194 (2001) 823-832
31. + regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J. Immunother. 25 (2002) 207-217
32. Rubinstein N., Alvarez M., Zwirner N.W., Toscano M.A., Ilarregui J.M., Bravo A., Mordoh J., Fainboim L., Podhajcer O.L., and Rabinovich G.A. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: a potential mechanism of tumor-immune privilege. Cancer Cell 5 (2004) 241-251
33. Yang Y., Huang C.T., Huang X., and Pardoll D.M. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol. 5 (2004) 508-515
34. Kevin E.K., Song X.T., Aldrich M., Huang X.F., and Chen S.Y. SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J.Clin. Invest. 116 (2006) 90-100